Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

160.63 +0.80 (+0.50%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
48 49 Next >
Biogen: Q4 Earnings Insights
  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year
Biogen's new Alzheimer's drug generated $1 million in fourth-quarter sales. 
Via Investor's Business Daily
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Biogen Q4 Earnings
  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter. 
Via Benzinga
Earnings Preview For Biogen
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely... 
Via Benzinga
Biogen Snags $2.3 Billion In Samsung Biosimilars Deal; So, What's Next?
Analysts say the company could make an acquisition or another strategic move. 
Via Investor's Business Daily
Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B
Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion. 
Via Benzinga
World Markets News for Tuesday
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon. 
Via Talk Markets
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has  
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
AskSlim Market Week - Friday, Jan. 28
Technical and cycle analysis, and market commentary. 
Via Talk Markets
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Monday
SVB Leerink cut Biogen Inc. (NASDAQ:BIIB) price ... 
Via Benzinga
14 Stocks in the Healthcare Sector
Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%. 
Via Talk Markets
10 Biggest Price Target Changes For Tuesday
Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ: 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
Two Curses Of The Current Year
The good news on inflation after this week's shocker is that December wholesale prices only rose 0.2%. 
Via Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
3 Biotech Stocks to Buy That Are Under Severe Pressure
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022
Upgrades According to Morgan Stanley, the prior rating for SunPower Corp (NASDAQ: 
Via Benzinga
Why Jim Cramer Prefers This Mining Stock Over Vale
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Thursday
RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on... 
Via Benzinga
This Is What Whales Are Betting On Biogen
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a... 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 12, 2022
Upgrades Citigroup upgraded the previous rating for Solo Brands Inc (NYSE: 
Via Benzinga
Why Biogen Shares Are Falling Today
Biogen Inc (NASDAQ: BIIB) is trading lower Wednesday following a U.S. Centers For Medicare listing for "Monoclonal Antibodies Directed Against Amyloid for the... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.